SCHEMBL215729

SCHEMBL215729

Cc1cc(F)cc(-c2nc(C(F)(F)F)cn2-c2ccc(S(C)(=O)=O)cc2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
PTGS2 P35354 19/20 1.00
PTGS1 P23219 8/20 0.83

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8886839 0.91 PTGS1 (1.00) PTGS2PTGS1
SCHEMBL214106 0.90 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL5594003 0.87 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL5594059 0.87 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL5594124 0.86 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL27563998 0.86 PTGS2 (0.75) PTGS2PTGS1
SCHEMBL5594267 0.86 PTGS2 (0.80) PTGS2PTGS1
SCHEMBL214198 0.86 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL3240027 0.85 PTGS2 (1.00) PTGS2PTGS1
SCHEMBL3246522 0.85 PTGS2 (1.00) PTGS2PTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 292 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1479385-B1 Use of cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia SEARLE LLC (US) 2008-07-02 EP claimed
CN-1332661-C Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors SEARLE & CO (US) 2007-08-22 CN claimed
EP-0843549-B1 COMPOSITIONS COMPRISING A CYCLOOXYGENASE-2 INHIBITOR AND A LEUKOTRIENE A 4 HYDROLASE INHIBITOR SEARLE & CO (US) 2006-04-12 EP claimed
CN-1660083-A Method of using benzenesulphoamides that are cyclooxygenase-2-inhibitors in the treatment and prevention of neoplasia G D SIORL & CO (US) 2005-08-31 CN claimed
EP-1536863-A1 USE OF CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THROMBOLYTIC AGENTS FOR THE TREATMENT OR PREVENTION OF A VASO-OCCLUSIVE EVENT Pharmacia Corporation (US) 2005-06-08 EP claimed
US-20050026902-A1 Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents PHARMACIA CORPORATION 2005-02-03 US claimed
EP-1463500-A1 USE OF COX-2 INHIBITORS IN COMBINATION WITH ANTIVIRAL AGENTS FOR THE TREATMENT OF PAPILLOMA VIRUS INFECTIONS PHARMACIA & UPJOHN COMPANY (US) 2004-10-06 EP claimed
US-20040186154-A1 Therapeutic combinations for cardiovascular and inflammatory indications SEIBERT KAREN (US) 2004-09-23 US claimed
EP-0932402-B1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA SEARLE LLC (US) 2004-07-21 EP claimed
US-20040138296-A1 Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease PHARMACIA CORPORATION 2004-07-15 US claimed
EP-0772600-B1 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION SEARLE & CO (US) 2002-09-18 EP claimed
US-20020035156-A1 Combination therapy in the prevention of cardiovascular disorders RONIKER BARBARA (US) 2002-03-21 US claimed
JP-2001527542-A 2001-12-25 JP claimed
CN-1247470-A Methods of using cyclooxygenase-2 inhibitors as anti-angiogenic agents SEARLE & CO (US) 2000-03-15 CN claimed
EP-0979077-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. Searle & Co. (US) 2000-02-16 EP claimed
CN-1244122-A Methods of treating and preventing neoplasia using cyclooxygenase-2 inhibitors SEARLE & CO (US) 2000-02-09 CN claimed
WO-1998047509-A1 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE PREVENTION OF CARDIOVASCULAR DISORDERS G.D. SEARLE & CO. (US) 1998-10-29 WO claimed
WO-1998016227-A9 METHOD OF USING CYCLOOXYGENASE-2 INHIBITORS IN THE TREATMENT AND PREVENTION OF NEOPLASIA 1998-07-30 WO claimed
EP-0772600-A1 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1997-05-14 EP claimed
WO-1996003388-A1 1,2-SUBSTITUTED IMIDAZOLYL COMPOUNDS FOR THE TREATMENT OF INFLAMMATION G.D. SEARLE & CO. (US) 1996-02-08 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020035156-A1 Combination therapy in the prevention of cardiovascular disorders FABP3, TNNT2, TNNI3 PTGS2 6/4885PTGS1 20/4885
US-20040138296-A1 Amyloid immunization and Cox-2 inhibitors for the treatment of alzheimer's disease APP, BACE2, PTGS2 PTGS2 3/4885PTGS1 9/4885
US-20040186154-A1 Therapeutic combinations for cardiovascular and inflammatory indications HMGCR, HMGB2, HMGB3 PTGS2 7/4885PTGS1 18/4885
US-20050026902-A1 Methods and compositions for the treatment or prevention of human immunodeficiency virus and related conditions using cyclooxygenase-2 selective inhibitors and antiviral agents PTGS2, PTGS1, PTGES2 PTGS2 1/4885PTGS1 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.